Patients can upgrade to medication with Purite twice daily

Since its introduction in 1996, brimonidine 0.2% (Alphagan, Allergan) has fast become a core member in the physician's arsenal of effective first-line IOP-lowering agents. Few find this surprising, given the drug's strong history in clinical trials proving its efficacy as a monotherapy,1 adjunctive, or replacement therapy.2,3 But as my fellow prescribers know, when opting for brimonidine 0.2%, some level of consideration is given to the possible occurrence of allergic conjunctivitis, which has been previously reported in 12.7% of patients.4